ArticleBreast (Edinburgh, Scotland)2020

Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.

Jean-Philippe Jacquin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.